🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

Synthesis and Cardiotropic Activity of 1-(Methoxybenzyl)-4-{2-[(Methoxybenzyl)-Amino]Ethyl}Piperazines


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A group of new 1-(methoxybenzyl)-4-{2-[(methoxybenzyl)amino]ethyl}piperazines (1) were synthesized. The relationship of the structure of the triazaalkane linker and the cardiotropic activity in a series of these compounds was compared with that of previously studied linear and cyclic methoxyphenyltriazaalkanes. The most active compound in the group was 1e (1-(3,4,5-trimethoxybenzyl)-4-{2-[(3,4,5-trimethoxybenzyl)amino] ethyl}piperazine trihydrochloride) with statistically significant antiarrhythmic activity in aconitine and CaCl2 arrhythmia models.

About the authors

G. V. Mokrov

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Author for correspondence.
Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

A. M. Likhosherstov

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

V. V. Barchukov

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

V. N. Stolyaruk

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

I. B. Tsorin

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

M. B. Vititnova

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

A. G. Rebeko

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

S. A. Kryzhanovskii

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

T. A. Gudasheva

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: g.mokrov@gmail.come
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature